2024 Revenues ($USD) : $28.16B

Takeda Pharmaceutical Company Limited reported total revenue of approximately $28.2 billion for its fiscal year ending March 31, 2024. This marked a dip compared to the roughly $30.3 billion booked in the prior fiscal year.

Despite the slip in the top line, the company maintained a sizable commitment to R&D, investing $4.8 billion during the fiscal year. While earlier quarterly reports had highlighted momentum in its Growth & Launch Products, the full-year numbers suggest this wasn't enough to offset challenges elsewhere in the portfolio.

On the corporate front, a key development came in January 2025 when Takeda announced its leadership succession plan. The board tapped Julie Kim, current head of the U.S. Business Unit and Global Portfolio Division, to eventually step into the President and CEO role when Christophe Weber retires in June 2026.

Looking down the road at the pipeline, Takeda indicated it's expecting three Phase 3 data readouts within the 2025 calendar year. Looking further out, the company projects three regulatory filings during its fiscal years 2025-2026, followed by five more in the fiscal '27-'29 window. Takeda seems optimistic about some of these late-stage assets, estimating six of these programs hold a combined peak revenue potential somewhere between USD 10 billion and 20 billion.

Takeda also signaled some moves for shareholders, announcing a share repurchase program to buy back up to JPY 100 billion of its stock and nudging up its adjusted free cash flow forecast for the fiscal year that ended March 31, 2025.